Clinical trial

Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD

NCT02576626

Study summary

ClinicalTrials.gov

Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention indacaterol/glycopyrronium 110/50 Breezhaler® Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention Placebo by Breezhaler® Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention Placebo by nebulisation Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-12-01

PhasePHASE4

Conditions

COPDverified · MONDO: chronic obstructive pulmonary disease

Interventions

indacaterol/glycopyrronium 110/50 Breezhaler®DRUG

Placebo by Breezhaler®DEVICE

ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisationDRUG

Placebo by nebulisationDEVICE

Sponsors & collaborators

Wouter H. van Geffenlead sponsor

Novartiscollaborator

University Medical Center Groningencollaborator

Mapped research locations

GroningenNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02576626 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.